Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran vs Warfarin in AF Ablation (RE-CIRCUIT)
NCT02348723Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2015
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 4, randomised, open-label trial of dabigatran in Atrial fibrillation (AFib) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Incidence of Major Bleeding Events (MBEs) as Defined by ISTH at 2 months. Started Apr 2015; status: completed.
02
Drugs
dabigatran
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT02348723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02348723.